Bristol Myers Squibb (CELG-RI) Land & Improvements (2025 - 2026)
Bristol Myers Squibb (CELG-RI) reported Land & Improvements of $157.0 million for Q1 2026, little changed quarter-over-quarter from $157.0 million in Q4 2025.
Bristol Myers Squibb (CELG-RI) Land & Improvements (2025 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 2 years of Land & Improvements data on file, last reported at $157.0 million in Q1 2026.
- Land & Improvements for Q1 2026 came in at $157.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $157.0 million (changed N/A YoY), and the FY2025 annual result was $157.0 million, changed N/A from the prior year.
- Land & Improvements was little changed at $157.0 million in Q1 2026 per CELG-RI's latest filing, from $157.0 million in the prior quarter.
- Over five years, Land & Improvements peaked at $157.0 million in Q4 2025 and troughed at $157.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 157.00 Mn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | 157.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 157.00 Mn |
| Dec 31, 2025 | 157.00 Mn |